Multiple Myeloma News

Here are all the latest news articles written by The Beacon's staff.

For news articles about treatments commonly given to myeloma patients, click on these links:
bisphosphonates, KyprolisPomalyst (Imnovid), Revlimid, thalidomide, Velcade, and Zometa.

For news articles about potential new myeloma treatments, click on these links:
ARRY-520 (filanesib), ACY-1215 (ricolinostat), afuresertib (GSK2110183), BT-062, daratumumab, elotuzumab, ixazomib (MLN9708),  marizomib (NPI-0052), MOR202, oprozomib, panobinostat, SAR650984, Treanda (bendamustine), and Zolinza (vorinostat).

For news articles about specific myeloma-related topics, click on these links:
bone disease, kidney failure, MGUS, maintenance therapy, peripheral neuropathysecondary cancer, smoldering multiple myeloma, and stem cell transplants.

[ by | Nov 6, 2014 5:18 pm | One Comment ]
Panobinostat Fails In Bid For FDA Advisory Committee Support

Panobinostat had an important appointment this morning with a group of on­col­o­gists.

The appointment did not go so well.

The Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) conducted a four-hour review of panobinostat (Farydak) earlier today.

At the end of the meeting, members of the committee were asked to vote whether they felt the benefits of panobinostat as a potential treatment for relapsed myeloma outweighed its risks.

Five committee members voted "no." Only two members voted "yes."

The advisory committee's vote is …

Read the full story »
[ by | Nov 6, 2014 4:08 am | 2 Comments ]
Live Coverage Of The Panobinostat FDA Advisory Committee Meeting

The Oncologic Drugs Advisory Committee of the U.S. Food and Drug Adminis­tra­tion will convene this morning to review pano­bino­stat, and The Myeloma Beacon will provide live coverage of the meeting.

Beacon staff members will post frequent updates at the webpage for this article as the meeting proceeds. Coverage will begin at the start of the meeting at 8 a.m. Eastern Time, which is when the review of pano­bino­stat (Farydak) is scheduled to begin.

The Swiss pharmaceutical company Novartis (NYSE:NVS) submitted an application to the Food and Drug Administration (FDA) …

Read the full story »
[ by | Nov 4, 2014 11:46 pm | 3 Comments ]
Panobinostat’s FDA Advisory Committee Meeting May Be A Bit Tougher Than Expected

As reported earlier today by The Beacon, the U.S. Food & Drug Admin­is­tra­tion (FDA) this morning released key documents related to the agen­cy’s review of pano­bino­stat as a potential new treatment for multiple myeloma.

The documents consist of briefing reports, agendas, and other sup­port­ing material for the meeting of the FDA’s Oncologic Drugs Advisory Com­mit­tee (ODAC) this coming Thursday. The morning session of that meet­ing will be devoted to a review of pano­bino­stat (Farydak), which is being developed by the Swiss pharmaceutical company Novartis (NYSE:NVS).

Among the documents released this …

Read the full story »
[ by | Nov 4, 2014 10:21 am | 2 Comments ]
FDA Releases Key Documents Related To Panobinostat Advisory Committee Meeting

The U.S. Food and Drug Administration this morning released important in­for­ma­tion related to its Oncologic Drugs Advisory Committee meeting scheduled for this Thursday, when the committee will review data related to the application by Novartis (NYSE:NVS) to have pano­bino­stat (Farydak) approved as a new treatment for multiple myeloma.

In addition to a draft agenda and draft committee roster, the Food and Drug Administration (FDA) released briefing information for the com­mit­tee members and a question about the risk/benefit profile of pano­bino­stat that the advisory committee will discuss and …

Read the full story »
[ by | Nov 3, 2014 9:25 am | 20 Comments ]
Evolution, Intra-Clonal Heterogeneity, And Multiple Myeloma

An important new concept in our understanding of multiple myeloma traces its origins back to the great nineteenth century scientist, Charles Darwin.

In his writings, Darwin described how char­acter­is­tics of animal and plant species can change over time. Slight differences in inherited char­acter­is­tics within a species, combined with variations in the en­viron­ment, can lead to certain char­acter­is­tics becoming more common in en­viron­ments favorable to those char­acter­is­tics.

A good example of what Darwin described is the range of size and shapes of beaks seen on Galápagos finches. The different beaks allow …

Read the full story »
[ by | Oct 26, 2014 8:33 pm | 22 Comments ]
New Criteria For The Diagnosis Of Multiple Myeloma And Related Disorders

The International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple myeloma.

The criteria have been published in The Lancet Oncology and are ac­com­panied by recommendations for monitoring and updated criteria for other related plasma cell disorders.

The new diagnostic criteria represent a paradigm shift in the approach to multiple myeloma and will have considerable impact on the management of the disease.

For decades, the diagnosis of multiple myeloma required the presence of “end-organ” damage that could be attributed to the underlying plasma cell disorder. Thus, …

Read the full story »